RMA
AZN icon

Roffman Miller Associates’s AstraZeneca AZN Stock Holding History

Roffman Miller Associates’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,938
Closed -$205K – 80
2020
Q2 		$205K Buy
+1,938
New +$200K 0.02% 143

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Roffman Miller Associates's AZN Position: Q3 2020 in Review

Roffman Miller Associates sold out of AstraZeneca (AZN) in Q3 2020, closing a stake of 1,938 shares — an estimated $205K sold.

Roffman Miller Associates first reported a position in AZN in Q2 2020 and held it in 1 quarter. The position peaked at $205K in Q2 2020. 722 funds tracked by Wall St. Rank hold AZN as of Q3 2020.

  • Roffman Miller Associates reported no remaining AstraZeneca position as of Q3 2020 after selling out during the quarter.
  • Roffman Miller Associates sold 1,938 AstraZeneca shares in Q3 2020, an estimated $205K.
  • Roffman Miller Associates first reported a position in AstraZeneca in Q2 2020 and held it in 1 quarter.
  • Roffman Miller Associates's AstraZeneca position peaked at $205K in Q2 2020.
  • 722 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2020.

Based on Roffman Miller Associates's 13F filing for Q3 2020, filed 6 Nov 2020.